Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947948 | 1.00 | CYP1A2 (0.45) | CYP1A2CYP3A4GABRR1GABBR2GABBR1 | |
| SCHEMBL2946324 | 1.00 | CYP1A2 (0.45) | CYP1A2CYP3A4GABRR1GABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL5372867 | 0.98 | CYP1A2 (0.44) | CYP1A2CYP3A4GABRR1GABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL9417109 | 0.98 | CYP1A2 (0.44) | CYP1A2CYP3A4GABRR1GABBR2GABBR1 | |
| SCHEMBL13444636 | 0.92 | GABRR1 (0.47) | CYP1A2CYP3A4GABRR1GABBR2GABBR1 | |
| SCHEMBL13444633 | 0.92 | GABRR1 (0.47) | CYP1A2CYP3A4GABRR1GABBR2GABBR1 | |
| SCHEMBL5379956 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL14559784 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL14559785 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL4047356 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673377-B1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-7186705-B2 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050070507-A1 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-31 | — | — | US | claimed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | claimed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-1673377-B1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20050070507-A1 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1000071-B1 | GABA-C RECEPTOR ANTAGONISTS FOR STIMULATING MEMORY CAPACITY | POLYCHIP PHARMACEUTICALS PTY (AU) | 2004-11-17 | — | — | EP | disclosed |
| US-6632806-B1 | Administering compound having selective GABAc receptor antagonist activity | THE UNIVERSITY OF SYDNEY (AU) | 2003-10-14 | — | — | US | disclosed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5407922-A | GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| US-5229379-A | Gamma-aminobutyric acid antagonists | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070507-A1 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | HTR5A, HPD, HNMT | CYP1A2 559/4885CYP3A4 825/4885GABRR1 4681/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | CYP1A2 3286/4885CYP3A4 4499/4885GABRR1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.